MRC Laboratory of Molecular Biology
AL-S Pharma release new data from AP-101 phase 2 trial for ALS
ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord
Lilly and WHO Foundation partner to support global dementia action plan
The partnership will provide financial support and strengthen early detection and intervention efforts
Lilly launches global Alzheimer’s campaign with Julianne Moore
The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health
TRIMTECH Therapeutics establishes Scientific Advisory Board
Alessio Ciulli has been appointed as Chair of the board
Roche shares promising data from Alzheimer’s disease development portfolio
The company is planning to initiate phase 3 studies of trontinemab in early AD this year
UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis
It is hoped that the test could be available for widespread UK use in the coming years
GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn
The licensing deal will give GSK access to ABL Bio's blood-brain barrier shuttle platform
Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review
Approximately 2.9 million people worldwide are living with the neurodegenerative disease
GSK to explore link between Shingrix and dementia risk in new UK research collaboration
More than 55 million people worldwide are currently living with the neurodegenerative disease
UK drug repurposing study identifies several potential dementia treatments
An estimated 982,000 people in the UK are currently living with the neurodegenerative disease
Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies
The neurodegenerative disease affects approximately 30,000 people in the US
Eli Lilly shares positive results for modified titration of Alzheimer’s drug donanemab
The neurodegenerative disorder accounts for up to 75% of the 982,000 dementia cases in the UK